Skip to main content
. Author manuscript; available in PMC: 2025 Mar 1.
Published in final edited form as: J Acquir Immune Defic Syndr. 2024 Mar 1;95(3):297–303. doi: 10.1097/QAI.0000000000003358

Table 2:

Week 2 AUC24, log10Cmax, log10Cmin and log10 Clearance. Mean differences by ABCG2 and NR1I2 genotype (Dominant Model). Adjustment variables included drug formulation cohort, weight, and sex.

Regression Model
Unadjusted Adjusted
Genotype PK Parameter Gene Levels n Mean Difference CI P-value Mean Difference CI P-value

ABCG2 AUC24(μg*h/mL) C/C 46
A/A or C/A 12 −12.80 (−28.29, 2.69) 0.11 −15.69 (−31.97, 0.58) 0.06
Cmax(μg/mL) C/C 46
A/A or C/A 12 −0.13 (−0.22, −0.03) 0.010 −0.15 (−0.25, −0.05) 0.003
Cmin(μg/mL) C/C 46
A/A or C/A 12 −0.14 (−0.34, 0.06) 0.17 −0.17 (−0.36, 0.02) 0.09
log Clearance (L/hr) C/C 47
A/A or C/A 12 0.06 (−0.14, 0.26) 0.54 0.10 (−0.03, 0.23) 0.13
NR1I2 AUC24(μg*h/mL) C/C 21
T/T or C/T 37 11.63 (−1.38, 24.64) 0.08 11.92 (−1.14, 24.99) 0.07
Cmax(μg/mL) C/C 21
T/T or C/T 37 0.05 (−0.04, 0.13) 0.27 0.05 (−0.03, 0.14) 0.22
Cmin(μg/mL) C/C 21
T/T or C/T 37 0.11 (−0.06, 0.28) 0.20 0.11 (−0.04, 0.27) 0.16
log Clearance (L/hr) C/C 22
T/T or C/T 37 −0.03 (−0.19, 0.14) 0.77 −0.08 (−0.18, 0.02) 0.14